Overactive Bladder (OAB)

6
Pipeline Programs
4
Companies
7
Clinical Trials
1 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
4
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
MIRABEGRONApproved
mirabegron
Unknown Company
beta3-Adrenergic Agonist [EPC]oral2022
U
MYRBETRIQApproved
mirabegron
Unknown Company
beta3-Adrenergic Agonist [EPC]oral2012
U
MYRBETRIQ GRANULESApproved
mirabegron
Unknown Company
beta3-Adrenergic Agonist [EPC]oral2021

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
3 programs
1
1
MirabegronPhase 41 trial
MirabegronPhase 31 trial
mirabegronN/A1 trial
Active Trials
NCT03602508Completed5,589Est. Sep 2019
NCT04641975Terminated26Est. Jul 2023
NCT02216214Completed888Est. Jan 2018
Salvat
SalvatFL - Miami
1 program
1
SVT-40776Phase 21 trial
Active Trials
NCT00507169CompletedEst. Sep 2007
Fempulse
2 programs
Device GroupN/A1 trial
FemPulse SystemN/A1 trial
Active Trials
NCT07195656RecruitingEst. Dec 2027
NCT06885099CompletedEst. Jul 2025
Pfizer
PfizerNEW YORK, NY
1 program
FesoterodineN/A1 trial
Active Trials
NCT01936870Completed2,521Est. May 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstellasMirabegron
AstellasMirabegron
SalvatSVT-40776
FempulseDevice Group
FempulseFemPulse System
Astellasmirabegron
PfizerFesoterodine

Clinical Trials (7)

Total enrollment: 9,024 patients across 7 trials

NCT02216214AstellasMirabegron

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Start: Oct 2014Est. completion: Jan 2018888 patients
Phase 4Completed
NCT04641975AstellasMirabegron

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

Start: Mar 2021Est. completion: Jul 202326 patients
Phase 3Terminated
NCT00507169SalvatSVT-40776

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Start: Sep 2006Est. completion: Sep 2007
Phase 2Completed
NCT07195656FempulseDevice Group

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

Start: Sep 2025Est. completion: Dec 2027
N/ARecruiting
NCT06885099FempulseFemPulse System

Ease of Use Study of the FemPulse System

Start: Feb 2025Est. completion: Jul 2025
N/ACompleted
NCT03602508Astellasmirabegron

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Start: Jul 2018Est. completion: Sep 20195,589 patients
N/ACompleted
NCT01936870PfizerFesoterodine

Drug Use Investigation for Toviaz

Start: Oct 2013Est. completion: May 20162,521 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 9,024 patients
4 companies competing in this space